FEMINE Study: Effectiveness of Oral Combination Kit Therapy in Syndromic Management of Abnormal Vaginal Discharge

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Ferari study_thumbnail
Detail Image
Ferari study_detailed
Book Detail
Actions
Download in App
Promotional Categories
Featured
Countries of release
Angola
Central African Republic (CAR)
Democratic Republic of the Congo (DRC)
Ghana
India
Kenya
Nigeria
UAE
Zambia
IS_Ebsco
false
Description

Vaginal discharge is a frequently reported concern among female patients. While often physiological, it can sometimes be polymicrobial, necessitating syndromic management with a combination of anti-infective agents. 
The recent FEMINE study published in 2024 explored the effectiveness of an oral combination therapy, Azimyn FS Kit, which includes 2 g secnidazole, 1 g azithromycin, and 150 mg fluconazole in treating infections among women at outpatient clinics in the Democratic Republic of Congo, and found that this combination therapy not only saved time, but also reduced the burden of testing. 
 

Click ‘Start Reading’ to explore the full study.

Published Date